Ali Sever
- Cancer Research top 2%
- Breast Cancer Treatment Studies 34
-
- Breast Lesions and Carcinomas 29
- Oncology top 5%
- Cancer Treatment and Pharmacology 6
- Cancer Risks and Factors 4
- HER2/EGFR in Cancer Research 4
- Surgery top 5%
- Breast Implant and Reconstruction 13
- Dermatology top 5%
-
- AI in cancer detection 7
-
- Advanced Breast Cancer Therapies 6
Ali Sever
53 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 95
- Cancer Research 764
- Pathology and Forensic Medicine 705
- Oncology 552
- Surgery 603
- Dermatology 93
Countries citing papers authored by Ali Sever
This map shows the geographic impact of Ali Sever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Sever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Sever more than expected).
Fields of papers citing papers by Ali Sever
This network shows the impact of papers produced by Ali Sever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Sever. The network helps show where Ali Sever may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ali Sever, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. | 2017 | 0 |
| 3 | Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. | 2017 | 0 |
| 4 | Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. | 2016 | 9 |
| 5 | Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. | 2016 | 7 |
| 6 | 2016 | 25 | |
| 7 | 2016 | 12 | |
| 8 | 2015 | 34 | |
| 9 | 2015 | 8 | |
| 10 | 2015 | 15 | |
| 11 | 2015 | 55 | |
| 12 | 2013 | 22 | |
| 13 | 2013 | 132 | |
| 14 | 2012 | 42 | |
| 15 | 2012 | 16 | |
| 16 | 2011 | 13 | |
| 17 | 2011 | 9 | |
| 18 | 2010 | 2 | |
| 19 | 2005 | 3 | |
| 20 | 2001 | 93 |
About Ali Sever
Ali Sever is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology, having authored 57 papers that have together received 1.4k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (34 papers), Breast Lesions and Carcinomas (29 papers), Breast Implant and Reconstruction (13 papers), AI in cancer detection (7 papers), Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (6 papers), Cancer Risks and Factors (4 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Cancer Research (764 citations), Pathology and Forensic Medicine (705 citations) and Oncology (552 citations). Ali Sever has collaborated with scholars based in United Kingdom, Türkiye and Netherlands. Frequent co-authors include Peter A. Jones, David E. Fish, Karina Cox, Kadri Altundağ, P. Mills, A. Özdemir Aktan, Susan Jones, J. Weeks, S.C.E. Diepstraten and Taner Babacan. Their work appears in journals such as European Journal of Surgical Oncology, Clinical Radiology, The Breast, SpringerPlus and American Journal of Roentgenology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.